Obstructive Lung Disease

Invasive Mechanical Ventilation May Improve Cystic Fibrosis Mortality Rates

Patients with cystic fibrosis who undergo invasive mechanical ventilation may have a lower risk for in-hospital mortality.

Bacterial Load: A Useful Marker of Antibiotic Response in Bronchiectasis

Bacterial load was a stable characteristic associated with worse quality of life and more airway inflammation in patients with bronchiectasis.

Final Height Impaired in Cystic Fibrosis After Rapid BMI Increase in Childhood

Final height was impaired in boys with cystic fibrosis who experienced a rapid increase in body mass index between the ages of 1 and 6.

Ivacaftor Approved for Cystic Fibrosis in Children as Young as 6 Months of Age

The FDA has expanded the indication for Kalydeco to include treatment of cystic fibrosis in patients 6 months of age and older.

Effects of Azithromycin on Pulmonary Exacerbations in Pediatric Cystic Fibrosis

Approximately 70% azithromycin users with cystic fibrosis returned to ≥90% of baseline FEV1 compared with 61% of azithromycin nonusers.

Small-Molecule Ion Channels Restore Host Defenses in CF Airway Epithelia

Unselective small-molecule ion channels can restore host defenses in the airway epithelia of patients with cystic fibrosis.

Antifibrinolytic Therapy Reduces Hemoptysis in Adults With Cystic Fibrosis

Systemic antifibrinolytic therapy in adult patients with cystic fibrosis has been associated with a reduced rate of hospital admissions for hemoptysis.

Biomarkers of Pancreatic Function in CF Improved With Lumacaftor/Ivacaftor

Improvements in pancreatic function biomarkers, including increases in fecal elastase-1 and decreases in serum immunoreactive trypsinogen, were seen in patients treated with lumacaftor and ivacaftor.